Marijuana and Cannabidiol Use Prevalence and Symptom Management Among Patients with Cancer.
Marijuana and Cannabidiol Use Prevalence and Symptom Management Among Patients with Cancer.
复制标题
DOI：
10.1158/2767-9764.crc-23-0233
复制
发表时间：
2023-09-22
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
疼痛、恶心和焦虑等症状在癌症患者中很常见。处理这些问题往往具有挑战性。大麻产品可能有助于减轻这些症状的严重程度。虽然一些研究包括关于癌症患者使用大麻的流行率的数据，但详细数据仍然有限，并且没有报告大麻二酚（CBD）在这一人群中的流行率。在2021年至2022年期间，在一家大型的、NCI指定的综合癌症中心的八家诊所就诊的成年癌症患者完成了一份详细的、以大麻为重点的问卷调查。符合条件的参与者被诊断患有浸润性癌症，并在过去12个月内接受治疗。计算了简要统计量，以描述大麻使用的抽样情况。约15%（n = 142）的知情同意患者（n = 934）报告了当前大麻使用（定义为过去12个月内使用）。其中，75%的人报告在过去一周使用大麻。在目前的大麻使用者中，39%（n = 56;总体6%）使用CBD产品。目前的使用者报告使用大麻的中位数为4.5（四分位数范围：0.6-7.0）天/周，2.0（1.0-3.0）次/天，3年（0.8-30.0）。使用模式因给药途径而异。患者报告使用大麻后症状中度至高度缓解。这项研究是迄今为止在大麻测量方面最详细的研究，并提供了有关活动性癌症中大麻使用现状的信息。未来的研究应包括对大麻产品使用、多个招募地点和不同患者人群的完整评估。临床医生应该意识到患者正在使用大麻产品，并通过使用大麻产品来缓解症状。
Symptoms such as pain, nausea, and anxiety are common in individuals with cancer. Treatment of these issues is often challenging. Cannabis products may be helpful in reducing the severity of these symptoms. While some studies include data on the prevalence of cannabis use among patients with cancer, detailed data remain limited, and none have reported the prevalence of cannabidiol (CBD) use in this population. Adult patients with cancer attending eight clinics at a large, NCI-designated Comprehensive Cancer Center completed a detailed, cannabis-focused questionnaire between 2021 and 2022. Eligible participants were diagnosed with invasive cancer and treated in the past 12 months. Summary statistics were calculated to describe the sample regarding cannabis use. Approximately 15% (n = 142) of consented patients (n = 934) reported current cannabis use (defined as use within the past 12 months). Among which, 75% reported cannabis use in the past week. Among current cannabis users, 39% (n = 56; 6% overall) used CBD products. Current users reported using cannabis a median of 4.5 (interquartile range: 0.6–7.0) days/week, 2.0 (1.0–3.0) times per use/day, and for 3 years (0.8–30.0). Use patterns varied by route of administration. Patients reported moderate to high relief of symptoms with cannabis use. This study is the most detailed to date in terms of cannabis measurement and provides information about the current state of cannabis use in active cancer. Future studies should include complete assessments of cannabis product use, multiple recruitment sites, and diverse patient populations. Clinicians should be aware that patients are using cannabis products and perceive symptom relief with its use.